The North America Melanoma Cancer Diagnostics Market demonstrates steady growth. Valued at USD 1,964.80 million in 2022, the market reaches USD 3,466.02 million by 2030, expanding at a CAGR of 7.4% during 2023–2030. This report analyzes market dynamics, segmentation, drivers, restraints, opportunities, and competitive landscape, based exclusively on Data Bridge Market Research insights.

Understanding Melanoma Cancer Diagnostics

Melanoma diagnostics study skin cells/molecules via tests like biomarkers (BRAF/NRAS/CKIT mutations), imaging (ultrasound, MRI, CT, PET), biopsy (optical/excisional/incisional/shave/punch), FISH, CGH, and IHC. Instruments (imaging: ultrasound/MRI/CT; biopsy; pathology: PCR/cell processors/slide staining/tissue processing) and consumables (kits: PCR/nucleic acid isolation/DNA polymerase; probes: Q FISH/flow FISH; reagents: assays/buffers/primers) enable precise detection. Globally, early diagnosis improves outcomes amid rising incidence.

Download Full Report Here : https://www.databridgemarketresearch.com/reports/north-america-melanoma-cancer-diagnostics-market

Market Size and Growth Projections

Rising melanoma prevalence and non-invasive preferences fuel growth. Valued at USD 1,964.80 million in 2022, the market reaches USD 3,466.02 million by 2030 at a CAGR of 7.4% (2023–2030).

U.S. dominates from quality healthcare and non-invasive demand. Countries: U.S., Canada, Mexico.

Market Segmentation

By Product Type

• Instruments → 41.5% share in 2025 (imaging: ultrasound/MRI/CT; biopsy; pathology: PCR/cell processors/slide staining/tissue processing).
• Consumables & Accessories → Fastest at 10.8% CAGR (kits: PCR/nucleic acid isolation/DNA polymerase; probes: Q FISH/flow FISH; reagents: assays/buffers/primers).
• Others

By Test Type

• Biomarkers Test → 38.6% share in 2025 (BRAF/NRAS/CKIT).
• Imaging Test → Fastest-growing (ultrasound/MRI/chest X-ray/lymphoscintigraphy/CT/PET).
• Biopsy (optical/excisional/incisional/shave/punch), FISH, CGH, IHC (S100/Melan-A/PMEL/Tyrosinase/MITF/SM5-1/CSPG4), Others.

By End User

• Hospitals → 45.2% share in 2025.
• Independent Diagnostic Laboratories → Fastest at 11.4% CAGR.
• Associated Labs, Diagnostic Imaging Centers, Cancer Research Institutes, Others

By Distribution Channel

• Direct Tender → 62% share in 2025.
• Retail Sales → Fastest at 12.1% CAGR.
• Others

Key Drivers Fueling Growth

• Rising demand for early diagnosis amid increasing melanoma incidence.
• Preference for non-invasive methods.
• Preventive health check-ups and awareness.
• Novel technologies and healthcare expenditure.

Restraints/Challenges

• Lack of skilled/certified professionals.
• High costs of diagnostics.
• Strict regulations for approval/commercialization.

Opportunities

• Increasing healthcare expenditure.
• Strategic initiatives (launches, collaborations).
• Government support.
• Non-invasive demand.

Competitive Landscape

Major players include:

• Sysmex Europe SE
• BIOMÉRIEUX
• Castle Biosciences, Inc.
• DermTech
• SYNLAB International
• Biohit Oyj
• Epigenomics AG
• Damae Medical
• SkylineDx
• AMLo Biosciences Ltd
• Oxford Gene Technology IP Limited
• HYPHEN BioMed
• Thermo Fisher Scientific Inc.
• Vermilion, Inc.
• Abbott
• F. Hoffmann-La Roche Ltd
• Siemens Healthineers AG
• DiaSorin S.p.A.

Recent developments:

• October 2022 → Quest Diagnostics/Decode Health collaboration for biomarker data in cancer diagnostics.
• May 2022 → Myriad Genetics/Intermountain Precision Genomics partnership for liquid biopsy.

Future Trends and Opportunities

Trends emphasize non-invasive and AI-assisted diagnostics. Opportunities in liquid biopsy and strategic partnerships.

Conclusion

The North America Melanoma Cancer Diagnostics Market advances to USD 3,466.02 million by 2030 at 7.4% CAGR, enabling early detection effectively. Stakeholders should leverage non-invasive innovations to address costs and seize awareness opportunities. Prioritizing U.S. demand will ensure diagnostic success.

Browse More Reports:

Global Tyrosine Kinase Inhibitors Market
Global VEGF-A Inhibitors Market
Global Wound Debridement Devices Market
Asia-Pacific Wound Debridement Devices Market
Europe Wound Debridement Devices Market
Middle East and Africa Wound Debridement Devices Market
North America Wound Debridement Devices Market
Europe Tissue Paper Market
North America Superhydrophobic Coating Market
Europe Sports Optics Market
Middle East and Africa Sports Optics Market
North America Sports Optics Market
North America Paper and Paperboard Packaging Market
Asia-Pacific Paper and Paperboard Packaging Market
Middle East and Africa Paper and Paperboard Packaging Market

About Data Bridge Market Research:

An absolute way to forecast what the future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact Us:
Data Bridge Market Research
US: +1 614 591 3140
UK: +44 845 154 9652
APAC : +653 1251 975
Email:- corporatesales@databridgemarketresearch.com